Arbutus Biopharma (ABUS) Reports FY18 Loss of $1.21

Arbutus Biopharma (NASDAQ: ABUS) reported FY18 EPS of ($1.21), versus ($1.56) reported last year. Revenue for the year came in at $5.9 million, versus $10.7 million reported last year.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Investing.com’s stocks of the week
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says